About ZOSTAVAX

ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia. ZOSTAVAX should not be used for prevention of primary varicella infection (Chickenpox).

Select Safety Information for ZOSTAVAX® (Zoster Vaccine Live)

Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients.

Do not administer ZOSTAVAX to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. Causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, leukemia, lymphoma or other malignant neoplasms affecting the bone marrow or lymphatic system, and immunosuppressive therapy.

A reduced immune response to ZOSTAVAX was observed in individuals who received concurrent administration of PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks.

Serious vaccine-related adverse reactions that have occurred following vaccination with ZOSTAVAX include asthma exacerbation and polymyalgia rheumatica. Other serious adverse events reported following vaccination with ZOSTAVAX include cardiovascular events (congestive heart failure, pulmonary edema). Common adverse reactions occurring in ≥1% of vaccinated individuals during clinical trials include injection-site reactions (erythema, pain/tenderness, swelling, hematoma, pruritus, warmth) and headache.

Transmission of vaccine virus may occur between vaccinees and susceptible contacts.

Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis.

Before administering ZOSTAVAX® (Zoster Vaccine Live), please read the accompanying Prescribing Information. The Patient Information also is available.

1. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database J Gen Intern Med. 2005;20(8):748–753.
2. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1163180-0015.
3. Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.
4. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(37). doi:10.1186/1741-7015-8-37.
5. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1203696-0003.
6. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1163180-0002.
7. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1163180-0016.
8. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1114216-0004.

Discussing Vaccination in the Pharmacy

  • Your Role
    Your Role

    If you don't recommend vaccination in your pharmacy, who will?

    Only 16% of patients are likely to ask their pharmacist about vaccination, according to a survey of approximately 500 adults aged 50 to 79 years.2
    Your recommendation plays an important role in their vaccination status.2

    Keep in mind that rules and regulations regarding administration of ZOSTAVAX in pharmacies differ from state to state and may also differ based on the age of the patient. Check your state Board of Pharmacy for state specific information.

  • Identify & Initiate
    Identify & Initiate

    Help protect appropriate adults against zoster

    Patients are in your pharmacy every day.
    Based on 2012 to 2014 IMS data, adults aged ≥50 years
    pick up prescriptions at the pharmacy up to 15 times a year.6
    Identify Patients Who Are Eligible for Herpes Zoster (Shingles) Vaccination

    Consider whether you have patients for whom ZOSTAVAX is appropriate

    In a study that evaluated the incidence rates of herpes zoster per 1,000 person-years utilizing healthcare claims during a 12-month period, from 2000 to 2001, of the Medstat MarketScan from ~4 million privately insured US individuals of all ages,
    The greatest number of zoster cases occurred in the 50 to 59 age cohorts.1
  • Educate
    Educate

    Patients look to you for vaccination7

    As their pharmacist, you have the opportunity to help protect adult patients.
    • Based on IMS data from 2015, adults aged 50 to 64 are more frequently vaccinated for herpes zoster in their pharmacy rather than in their physician's office.7
  • Recommend & Vaccinate
    Recommend & Vaccinate

    When recommending vaccination - Your words matter

    Consider 3 key phrases to get the vaccination conversation started:
    1. "I've seen how debilitating shingles can be. This is not a disease you want to get."
    2. Sharing a personal or professional experience can help your patients understand the real impact this disease can have.3
    3. "This vaccine can help prevent shingles."
    4. Help patients understand the potential benefits as well as the potential side effects and limitations of the vaccine.3
    5. "I recommend you get vaccinated."
    6. Your patients trust you as a health care provider. They want more than just the facts about vaccination; they want to know why you recommend it.
    Keep in mind that rules and regulations regarding administration of ZOSTAVAX in pharmacies differ from state to state and may also differ based on the age of the patient. Check your state Board of Pharmacy for state-specific information.

About ZOSTAVAX

ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia. ZOSTAVAX should not be used for prevention of primary varicella infection (Chickenpox).

Select Safety Information for ZOSTAVAX® (Zoster Vaccine Live)

Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients.

Do not administer ZOSTAVAX to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. Causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, leukemia, lymphoma or other malignant neoplasms affecting the bone marrow or lymphatic system, and immunosuppressive therapy.

A reduced immune response to ZOSTAVAX was observed in individuals who received concurrent administration of PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks.

Serious vaccine-related adverse reactions that have occurred following vaccination with ZOSTAVAX include asthma exacerbation and polymyalgia rheumatica. Other serious adverse events reported following vaccination with ZOSTAVAX include cardiovascular events (congestive heart failure, pulmonary edema). Common adverse reactions occurring in ≥1% of vaccinated individuals during clinical trials include injection-site reactions (erythema, pain/tenderness, swelling, hematoma, pruritus, warmth) and headache.

Transmission of vaccine virus may occur between vaccinees and susceptible contacts.

Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis.

Before administering ZOSTAVAX® (Zoster Vaccine Live), please read the accompanying Prescribing Information. The Patient Information also is available.

VACC-1133787-0020 05/18